Gumarontinib
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Gumarontinib is a pharmaceutical drug used for the treatment of cancer. In China, it was conditionally approved in 2023 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation. Gumarontinib is a selective MET—hepatocyte growth factor receptor—inhibitor.
Gumarontinib is a pharmaceutical drug used for the treatment of cancer. In China, it was conditionally approved in 2023 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation. Gumarontinib is a selective MET—hepatocyte growth factor receptor—inhibitor.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1353499630 under CC BY-SA 4.0; modifications have been made.